JTJoke Terryn

Joke Terryn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joke Terryn has a total of 62 co-authors. Here are the top co-authors by number of shared publications:

  • Catherine M. Verfaillie

    Department of Development and Regeneration, Stem Cell Institute, KU Leuven, Leuven, Belgium

    4 shared publications
  • Andreas Ebneth

    Janssen Research & Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium

    2 shared publications
  • Juan Antonio García-León

    Departamento Biologia Celular, Genetica y Fisiologia, Instituto de Investigacion Biomedica de Malaga-IBIMA, Facultad de Ciencias, Universidad de Malaga, 29071 Malaga, Spain

    2 shared publications
  • Kristel Eggermont

    Department of Development and Regeneration, Stem Cell Biology and Embryology, KU Leuven Stem Cell Institute, Leuven, Belgium

    2 shared publications
  • Philip Van Damme

    Laboratory of Neurobiology, Center for Brain & Disease Research, VIB, 3000 Leuven, Belgium

    2 shared publications
  • Raheem Fazal

    Department of Development and Regeneration, Stem Cell Biology and Embryology, KU Leuven Stem Cell Institute, Leuven, Belgium; KU Leuven-Department of Neurosciences, Experimental Neurology and Leuven Research Institute for Neuroscience and Disease (LIND), Leuven, Belgium; VIB Center for Brain and Disease Research, Laboratory of Neurobiology, Leuven, Belgium

    2 shared publications

Latest Publications

  • Open Access

    Intracerebroventricular delivery of vascular endothelial growth factor in patients with amyotrophic lateral sclerosis, a phase I study

    by Philip Van Damme, Petra Tilkin, Katarina Jansson Mercer, Joke Terryn, Ann D’hondt, Nina Herne, Thomas Tousseyn, Kristl G Claeys, Dietmar R Thal, Olof Zachrisson, et al.

    We studied the feasibility, safety, tolerability and pharmacokinetics of intracerebroventricular delivery of recombinant human vascular endothelial growth factor in patients with amyotrophic lateral sclerosis. In this phase I study in patients with amyotrophic lateral sclerosis, the study drug was delivered using an implantable programmable pump connected to a catheter inserted in the frontal horn of the lateral cerebral ventricle. A first cohort received open label vascular endothelial growth factor (0.2, 0.8 and 2 µg/day), a second cohort received placebo, 0.8 or 2 µg/day of study dug. After the 3-month study period, all patients could participate in an open label extension study. In total, 18 patients with amyotrophic lateral sclerosis, seen at the University Hospitals in Leuven were included. The surgical procedure was well tolerated in most patients. One patient had transient postoperative seizures, due to an ischemic lesion along the catheter tract. The first 3-month study period was completed by 15/18 patients. Administration of 2 µg/day vascular endothelial growth factor resulted in sustained detectable levels in cerebrospinal fluid. A pulmonary embolus occurred in 3 patients, in 1 patient in the first 3-month study, and in 2 patients during the open label extension study. The study drug was well tolerated in the other patients, for up to 6 years in the open label extension study. Our study shows that intracerebroventricular administration of 2 µg/day of vascular endothelial growth factor to patients with amyotrophic lateral sclerosis is feasible, results in detectable cerebrospinal fluid levels and is well tolerated in most patients. The most common serious adverse event was a pulmonary embolus.


  • The Characteristic Eye Movement Disorder of RFC1‐Linked CANVAS

    by Joke Terryn, Amélie Van Eesbeeck, Sascha Vermeer, Wim Vandenberghe

    View Supplementary Video 1 View Supplementary Video 2 View Supplementary Video 3


  • Open Access

    Topographical Guidance of PSC-Derived Cortical Neurons

    by Joke Terryn, Marleen Welkenhuysen, Olga Krylychkina, Andrea Firrincieli, Alexandru Andrei, Veerle Reumers, Philip Van Damme, Dries Braeken, Catherine Verfaillie

    Background and Aims. Human pluripotent stem cell- (PSC-) derived neurons are increasingly used in the study of neurodevelopmental and neurodegenerative diseases. Electrophysiological activity is a crucial and defining function of these neurons. Patch clamping and the more recently developed multielectrode arrays are used to evaluate this complex function. In this study, we assess the effect of topography on PSC-derived neurons as a baseline for the development of next-generation silicon oxide substrates (in direct relation to MEA fabrication) that integrate topography as a means to guide network formation and stimulate differentiation. Methods. Human PSC was differentiated towards cortical neurons and seeded on a silicon micropatterned substrate to screen for topographic guidance and improved neurite outgrowth. We next developed customized micropillar and microgroove substrates to further assess the effect of topography on human cortical neurons. Immunocytochemistry and morphological analyses were used to track neuron differentiation and guidance. Results. Microgroove and micropillar substrates appeared to support the differentiation of human stem cell-derived cortical neurons, promoted neurite outgrowth, and facilitated contact guidance. In contrast to flat surfaces, topography also appeared to limit the number of NESTIN positive neuronal progenitor cells present in the culture. Conclusion. We describe the topographical preferences of human PSC-derived cortical neurons, on neurite outgrowth and guidance. Embedding topography in silicon substrates may be an effective approach to direct and improve neuronal network formation. We propose to integrate topography in multielectrode arrays as a practical method to shape the neuro-electronic interface.


  • Open Access

    Generation of a human induced pluripotent stem cell–based model for tauopathies combining three microtubule‐associated protein TAU mutations which displays several phenotypes linked to neurodegeneration

    by Juan Antonio García‐León, Alfredo Cabrera‐Socorro, Kristel Eggermont, Ann Swijsen, Joke Terryn, Raheem Fazal, FatemehArefeh Nami, Laura Ordovás, Ana Quiles, Frederic Lluis, et al.

    Introduction: Tauopathies are neurodegenerative diseases characterized by TAU protein–related pathology, including frontotemporal dementia and Alzheimer's disease among others. Mutant TAU animal models are available, but none of them faithfully recapitulates human pathology and are not suitable for drug screening.Methods: To create a new in vitro tauopathy model, we generated a footprint‐free triple MAPT‐mutant human induced pluripotent stem cell line (N279K, P301L, and E10+16 mutations) using clustered regularly interspaced short palindromic repeats‐FokI and piggyBac transposase technology.Results: Mutant neurons expressed pathogenic 4R and phosphorylated TAU, endogenously triggered TAU aggregation, and had increased electrophysiological activity. TAU‐mutant cells presented deficiencies in neurite outgrowth, aberrant sequence of differentiation to cortical neurons, and a significant activation of stress response pathways. RNA sequencing confirmed stress activation, demonstrated a shift toward GABAergic identity, and an upregulation of neurodegenerative pathways.Discussion: In summary, we generated a novel in vitro human induced pluripotent stem cell TAU‐mutant model displaying neurodegenerative disease phenotypes that could be used for disease modeling and drug screening.


  • Open Access

    Recent advances in lineage differentiation from stem cells: hurdles and opportunities?

    by Joke Terryn, Tine Tricot, Madhavsai Gajjar, Catherine Verfaillie

    Pluripotent stem cells have the property of long-term self-renewal and the potential to give rise to descendants of the three germ layers and hence all mature cells in the human body. Therefore, they hold the promise of offering insight not only into human development but also for human disease modeling and regenerative medicine. However, the generation of mature differentiated cells that closely resemble their in vivo counterparts remains challenging. Recent advances in single-cell transcriptomics and computational modeling of gene regulatory networks are revealing a better understanding of lineage commitment and are driving modern genome editing approaches. Additional modification of the chemical microenvironment, as well as the use of bioengineering tools to recreate the cellular, extracellular matrix, and physical characteristics of the niche wherein progenitors and mature cells reside, is now being used to further improve the maturation and functionality of stem cell progeny.


  • [P3–080]: AN ACADEMIC‐PRIVATE PARTNERSHIP FOR THE VALIDATION OF NEW MODELS TO UNDERSTAND TAU‐RELATED HYPEREXCITABILITY AND AGGREGATION USING HUMAN‐INDUCED PLURIPOTENT STEM CELLS

    by Juan Antonio Garcia Leon, Francisco Pestana, Mohamed Kreir, Pei‐Yu Shih, Kristel Eggermont, Joke Terryn, Tina Charlotte Stumman, Martine Geraerts, Peter James Craig, Hugh Norman Nuthall, et al.

  • Stem cells in neurodegeneration: mind the gap

    by Christel Claes, Joke Terryn, Catherine M. Verfaillie